Helix BioPharma Corp. (HBPCF)

Helix BioPharma Cash Flow Statement

Financials in millions CAD. Fiscal year is August - July.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021
Net Income	-5.21	-9.26	-6.29	-6.56	-8.04
Depreciation & Amortization	0.01	0.01	0.01	0.01	0.2
Loss (Gain) From Sale of Assets	-0.02	-	-0.01	-	-
Loss (Gain) From Sale of Investments	-	-	-	-	-1.54
Stock-Based Compensation	0.18	3.52	0.57	0.43	0.66
Other Operating Activities	-0.13	0.03	0	0.51	0.09
Change in Accounts Receivable	-0.07	0.01	0.22	0.07	-0.17
Change in Accounts Payable	1.3	0.67	-0.07	-0.87	0.05
Change in Other Net Operating Assets	0.1	-0.19	0.04	-0.1	0.07
Operating Cash Flow	-3.83	-5.22	-5.53	-6.51	-9.3
Capital Expenditures	-0	-0.01	-0.01	-	-
Sale of Property, Plant & Equipment	0.02	-	0.01	-	-
Divestitures	-	-	-	-	2.02
Investing Cash Flow	0.02	-0.01	-0.01	-	2.02
Long-Term Debt Issued	-	-	-	-	3.16
Long-Term Debt Repaid	-	-	-2.06	-	-0.16
Net Debt Issued (Repaid)	-	-	-2.06	-	3
Issuance of Common Stock	2.8	5.51	5.63	6.21	3.56
Other Financing Activities	-	-	-0.48	-	-
Financing Cash Flow	2.8	5.51	3.09	6.21	6.56
Foreign Exchange Rate Adjustments	-	-	-	-0.01	0.05
Net Cash Flow	-1.02	0.27	-2.44	-0.31	-0.67
Free Cash Flow	-3.83	-5.23	-5.54	-6.51	-9.3
Free Cash Flow Per Share	-0.07	-0.12	-0.14	-0.22	-0.34
Cash Income Tax Paid	-0.01	-	-	-	-
Levered Free Cash Flow	-1.86	-2.75	-2.2	-4.24	-4.8
Unlevered Free Cash Flow	-1.85	-2.74	-2.19	-4.23	-4.79
Change in Working Capital	1.33	0.49	0.19	-0.89	-0.05

Updated Jul 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.